Related Experiment Video
Updated: Jul 12, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Pioglitazone hydrochloride/glimepiride.
1South Carolina College of Pharmacy, University of South Carolina Campus, Columbia, SC 29208, USA. blake@cop.sc.edu
Drugs of Today (Barcelona, Spain : 1998)
|August 31, 2007
Summary
The combination of pioglitazone and glimepiride effectively manages type 2 diabetes by improving insulin sensitivity and reducing hemoglobin A1c levels. This oral therapy also offers cardiovascular benefits and is generally well-tolerated with minimal side effects.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) management requires effective oral agents.
- Pioglitazone (thiazolidinedione) and glimepiride (sulfonylurea) are established T2DM medications.
- Combination therapy aims to enhance glycemic control and provide broader benefits.
Purpose of the Study:
- To summarize the therapeutic profile of pioglitazone and glimepiride combination therapy for type 2 diabetes.
- To highlight the combined effects on glycemic control, lipid profiles, blood pressure, and cardiovascular outcomes.
- To review the safety and tolerability of this combination regimen.
Main Methods:
- Review of pharmacological actions of pioglitazone and glimepiride.
- Analysis of clinical data on combination therapy efficacy and safety.
- Examination of effects on hemoglobin A1c, lipid profiles, blood pressure, and cardiovascular events.
Main Results:
- Combination therapy significantly reduces hemoglobin A1c levels by 1-2%.
- Pioglitazone enhances insulin sensitivity; glimepiride stimulates insulin secretion.
- Favorable effects observed on lipid profiles, blood pressure, and reduced risk of cardiovascular events.
- Common side effects include weight gain and edema; heart failure risk is low but requires monitoring.
Conclusions:
- Pioglitazone and glimepiride combination is an effective oral treatment for type 2 diabetes.
- The regimen offers comprehensive benefits including glycemic control, cardiovascular protection, and improved metabolic parameters.
- Generally well-tolerated, with careful patient selection and monitoring advised.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...